We assessed the efficacy of radical prostatectomy (RP) in prostate cancer patients with preoperative prostate-specific antigen (PSA) levels ≥ 20 ng/ml and no distant metastases.
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8 Prostate-specific antigen (PSA) progression-free probability in radical prostatectomy (RP) patients with an initial PSA ≥20 ng/ml. (A) Overall PSA progression-free probability. (B) PSA progression-free probability in the groups with PSA 20-40 ng/ml and ≥40 ng/ml. Data presented as number of patients, with percentages in parentheses, unless otherwise noted. PSA: prostate-specific antigen, RP: radical prostatectomy (p=0.719, 1.000)( Table 2) 
